Your browser is no longer supported. Please, upgrade your browser.
Settings
QDEL Quidel Corporation daily Stock Chart
QDEL [NASD]
Quidel Corporation
Index- P/E364.56 EPS (ttm)0.10 Insider Own1.40% Shs Outstand33.22M Perf Week0.51%
Market Cap1.25B Forward P/E87.33 EPS next Y0.43 Insider Trans-38.83% Shs Float27.43M Perf Month37.14%
Income3.90M PEG18.23 EPS next Q-0.18 Inst Own92.30% Short Float11.70% Perf Quarter53.27%
Sales215.00M P/S5.80 EPS this Y-136.80% Inst Trans0.05% Short Ratio11.03 Perf Half Y95.27%
Book/sh6.63 P/B5.66 EPS next Y2.38% ROA1.00% Target Price32.33 Perf Year91.09%
Cash/sh5.95 P/C6.32 EPS next 5Y20.00% ROE1.90% 52W Range18.25 - 38.92 Perf YTD75.30%
Dividend- P/FCF35.24 EPS past 5Y-31.00% ROI-0.60% 52W High-3.52% Beta1.33
Dividend %- Quick Ratio7.60 Sales past 5Y3.90% Gross Margin63.80% 52W Low105.75% ATR1.29
Employees627 Current Ratio8.40 Sales Q/Q46.50% Oper. Margin8.50% RSI (14)88.17 Volatility2.66% 3.62%
OptionableYes Debt/Eq0.68 EPS Q/Q499.20% Profit Margin1.80% Rel Volume1.75 Prev Close37.82
ShortableYes LT Debt/Eq0.68 EarningsJul 26 AMC Payout0.00% Avg Volume291.06K Price37.55
Recom2.10 SMA2024.39% SMA5037.77% SMA20063.44% Volume509,764 Change-0.71%
Jul-18-17Upgrade William Blair Mkt Perform → Outperform
Jul-18-17Upgrade Canaccord Genuity Hold → Buy $25 → $42
Apr-25-17Reiterated Canaccord Genuity Hold $24 → $24.50
Feb-17-17Initiated CL King Neutral
Dec-16-16Downgrade Piper Jaffray Overweight → Neutral
Jun-13-16Upgrade Raymond James Mkt Perform → Outperform
Feb-18-16Reiterated Barclays Overweight $28 → $22
Feb-09-16Downgrade Canaccord Genuity Buy → Hold $22 → $18
Jan-08-16Reiterated Canaccord Genuity Buy $25 → $22
Dec-14-15Downgrade Raymond James Outperform → Mkt Perform
Sep-02-15Initiated Barclays Overweight $28
Jul-31-13Reiterated Canaccord Genuity Buy $30 → $35
Mar-03-11Downgrade Wedbush Outperform → Neutral $14 → $13
Nov-16-10Initiated Canaccord Genuity Buy $18
May-27-10Upgrade Wedbush Neutral → Outperform $15
Apr-07-10Initiated Wedbush Neutral $15
Sep-30-09Initiated William Blair Mkt Perform
Sep-11-09Reiterated Wedbush Morgan Underperform $11 → $12
Aug-06-09Downgrade Wedbush Morgan Neutral → Underperform $11
Jul-23-09Reiterated Caris & Company Average $11 → $13
Jul-19-17 03:56PM  Alere, St. Jude Deals in Focus as Abbott Releases Q2 Earnings TheStreet.com
07:00AM  Corporate News Blog - Quidel to Acquire Alere Triage(R) Assets Accesswire
Jul-18-17 05:21PM  Quidel Diversifies With Alere's Triage Assets TheStreet.com +9.50%
02:27PM  Abbott's Tarnished Deal Sparkles for Another Bloomberg
01:04PM  Here's Why Quidel Corporation Is Rising Today Motley Fool
08:20AM  Quidel (QDEL) Worth a Look: Stock Jumps 25.4% in Session Zacks
Jul-17-17 06:00AM  Quidel Announces Definitive Agreement to Acquire Alere Triage® Assets Business Wire +25.35%
Jul-14-17 04:05PM  Quidel to Hold Second Quarter 2017 Financial Results Conference Call on July 26, 2017 Business Wire
Jun-28-17 03:45PM  Quidel Receives FDA Clearance and CLIA Waiver for Its Point-of-Care Sofia® 2 Instrument for Use with Sofia Respiratory Syncytial Virus (RSV) Assay Business Wire
12:26AM  Edited Transcript of QDEL earnings conference call or presentation 24-Apr-17 9:00pm GMT Thomson Reuters StreetEvents
Jun-22-17 06:45PM  Quidels Sofia® 2 Point-of-Care Immunoassay Analyzer Receives Multiple Awards from Good Design Australia®s 2017 Good Design Awards® Business Wire
Jun-07-17 06:00PM  Quidel Receives the CE Mark for Its Thyretain® TBI Reporter BioAssay Business Wire
May-30-17 02:15PM  Quidel Receives FDA Clearance and CLIA Waiver for Its Point-of-Care Sofia® 2 Immunoassay Analyzer for Use with Sofia Influenza A+B Assay Business Wire
May-24-17 06:30PM  Quidel Receives PMDA Approval for Its Point-of-Care Sofia® Influenza A+B Assay Business Wire
May-18-17 01:58PM  ETFs with exposure to Quidel Corp. : May 18, 2017 Capital Cube
May-16-17 05:15PM  Quidel Completes Acquisition of InflammaDry(R) and AdenoPlus(R) Eye-Health Businesses Marketwired
May-11-17 02:30PM  Quidel Receives FDA Clearance for Its New Solana(R) Molecular Assay for the Detection of Clostridium difficile (C. difficile) Infections Marketwired
May-02-17 04:31PM  ETFs with exposure to Quidel Corp. : May 2, 2017 Capital Cube
May-01-17 05:30PM  Quidel to Present at the Bank of America Merrill Lynch 2017 Health Care Conference Marketwired
11:13AM  Quidel Corp. :QDEL-US: Earnings Analysis: Q1, 2017 By the Numbers : May 1, 2017 Capital Cube
Apr-26-17 08:31AM  Edited Transcript of QDEL earnings conference call or presentation 24-Apr-17 9:00pm GMT Thomson Reuters StreetEvents
Apr-24-17 05:00PM  Quidel posts 1Q profit Associated Press
04:10PM  Quidel Reports First Quarter 2017 Financial Results Marketwired
Apr-11-17 07:00PM  Quidel to Hold First Quarter 2017 Financial Results Conference Call on April 24, 2017 Marketwired
Apr-07-17 09:37AM  PetMed Faces Concerns over New Order Sales, Competition Zacks
Apr-06-17 08:30AM  Strength Seen in Alere (ALR): Stock Adds 9.4% in Session Zacks
Apr-04-17 09:30AM  Zacks.com featured highlights: Heska, Quidel, Trinseo S.A., Advanced Energy Industries and Pioneer Natural Resources Zacks
Apr-03-17 08:20AM  5 Stocks with Solid Efficiency Ratio to Buy in April Zacks
Mar-24-17 09:30AM  Zacks Industry Outlook Highlights: Quidel, OraSure Technologies, ResMed, Inogen and Masimo Zacks
Mar-22-17 08:25AM  OraSure Technologies (OSUR) In Focus: Stock Jumps 8.4% Zacks
Mar-16-17 09:30AM  The Zacks Analyst Blog Highlights: Health Insurance Innovations, Big 5 Sporting Goods, Quidel, Planet Payment and Bridgepoint Education Zacks
Mar-15-17 01:33PM  Small Caps Back to Breakeven for 2017, Buy These 5 Stocks on the Dip Zacks
08:35AM  Orthofix International (OFIX) Looks Good: Stock Jumps 9.9% Zacks
Mar-13-17 04:19PM  QUIDEL CORP /DE/ Files SEC form 8-K, Regulation FD Disclosure
Mar-02-17 06:00PM  Quidel to Present at the Barclays Global Healthcare Conference Marketwired
Feb-28-17 04:57PM  QUIDEL CORP /DE/ Files SEC form 8-K, Change in Directors or Principal Officers
Feb-22-17 01:04PM  QUIDEL CORP /DE/ Financials
Feb-21-17 05:04PM  QUIDEL CORP /DE/ Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
Feb-17-17 07:36AM  Coverage initiated on Quidel by CL King
Feb-16-17 05:15PM  QUIDEL CORP /DE/ Files SEC form 10-K, Annual Report
Feb-15-17 11:13AM  Quidel Corp. :QDEL-US: Earnings Analysis: Q4, 2016 By the Numbers : February 15, 2017 Capital Cube
Feb-10-17 02:01PM  Quidel Corp. :QDEL-US: Earnings Analysis: 2016 By the Numbers : February 10, 2017
Feb-08-17 09:53PM  Edited Transcript of QDEL earnings conference call or presentation 8-Feb-17 10:00pm GMT
05:18PM  Quidel reports 4Q loss
05:00PM  Quidel Corp Earnings Call scheduled for 5:00 pm ET today
04:18PM  QUIDEL CORP /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:10PM  Quidel Reports Fourth Quarter and Full Year 2016 Financial Results Marketwired
07:07AM  Q4 2016 Quidel Corp Earnings Release - After Market Close
Jan-25-17 04:30PM  Quidel to Hold Fourth Quarter and Full Year 2016 Financial Results Conference Call on February 8, 2017 Marketwired
Jan-24-17 06:09AM  QUIDEL CORP /DE/ Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Jan-23-17 07:00PM  Quidel Announces Modification of Revenue Reporting Categories Marketwired
Jan-06-17 04:18PM  QUIDEL CORP /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Financi
04:10PM  Quidel Announces Preliminary Revenue for Fourth Quarter 2016 Marketwired
Dec-20-16 04:10PM  Quidel to Present at 35th Annual J.P. Morgan Healthcare Conference Marketwired
10:09AM  Quidel Corp. Value Analysis (NASDAQ:QDEL) : December 20, 2016
Dec-19-16 07:48AM  Quidel Corp. breached its 50 day moving average in a Bearish Manner : QDEL-US : December 19, 2016
Dec-13-16 11:47AM  ETFs with exposure to Quidel Corp. : December 13, 2016
Dec-10-16 09:37PM  Should You Add Corcept Therapeutics Incorporated (CORT) To Your Portfolio? at Insider Monkey
Dec-02-16 04:17PM  QUIDEL CORP /DE/ Files SEC form 8-K, Termination of a Material Definitive Agreement
Nov-30-16 01:00PM  ETFs with exposure to Quidel Corp. : November 30, 2016
Nov-29-16 10:00AM  Quidel Receives FDA Clearance for Its New Solana(R) Molecular Assay for the Detection of Herpes Simplex Virus 1+2 and Varicella Zoster Virus Marketwired
Nov-17-16 04:30PM  Quidel to Present at the 28th Annual Piper Jaffray Healthcare Conference Marketwired
Nov-02-16 02:07PM  ETFs with exposure to Quidel Corp. : November 2, 2016
Oct-31-16 11:24AM  Quidel Corp. :QDEL-US: Earnings Analysis: Q3, 2016 By the Numbers : October 31, 2016
Oct-28-16 06:03AM  QUIDEL CORP /DE/ Files SEC form 10-Q, Quarterly Report -6.36%
Oct-27-16 09:33AM  Thermo Fisher (TMO) Tops Q3 Earnings, Raises '16 Outlook
09:32AM  NuVasive (NUVA) Earnings & Revenues Miss Estimates in Q3
09:30AM  Abaxis (ABAX) Q2 Earnings & Revenues Miss, Margins Slide
09:29AM  Mead Johnson (MJN) Tops Q3 Earnings, Lags Sales, Guides Low
06:51AM  Cardiovascular Systems (CSII) Q1 Loss Lower than Expected
Oct-26-16 11:44PM  Edited Transcript of QDEL earnings conference call or presentation 26-Oct-16 9:00pm GMT
06:33PM  Quidel reports 3Q loss
05:00PM  Quidel Corp Earnings Call scheduled for 5:00 pm ET today
04:21PM  QUIDEL CORP /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:10PM  Quidel Reports Third Quarter 2016 Financial Results Marketwired
10:40AM  ResMed (RMD) Misses Earnings & Revenue Estimates in Q1
10:33AM  LabCorp (LH) Q3 Earnings Miss, Revenues in Line; Guides Up
10:15AM  Boston Scientific's (BSX) Q3 Earnings in Line, Guides Up
07:15AM  Edwards Lifesciences (EW) Q3 Earnings in Line, Sales Miss
07:07AM  Q3 2016 Quidel Corp Earnings Release - After Market Close
Oct-25-16 04:10PM  Quidel Receives FDA Clearance for Its New Solana(R) Strep Complete Assay for Rapid and Qualitative Detection and Differentiation of S. pyogenes (Group A Beta-Hemolytic Streptococcus) and S. dysgalactiae (Pyogenic Group C and G Beta-Hemolyti Marketwired
09:01AM  PetMed (PETS) Earnings Miss, Revenues Top Estimates in Q2
08:46AM  Quidel Corp. breached its 50 day moving average in a Bullish Manner : QDEL-US : October 25, 2016
Oct-20-16 04:05PM  Walgreens Boots (WBA) Earnings Top, Margins Slide in Q4
Oct-14-16 08:57AM  Medtronic: FDA OKs MRI Scan-Compatible Cardiac Devices
Oct-13-16 09:39AM  QIAGEN's High-Throughput Solutions for Human ID Database
Oct-12-16 04:30PM  Quidel to Hold Third Quarter 2016 Financial Results Conference Call on October 26, 2016 Marketwired
09:13AM  Myriad Genetics Reports Encouraging myChoice HRD Data
08:44AM  Quidel Corp. breached its 50 day moving average in a Bearish Manner : QDEL-US : October 12, 2016
07:35AM  Teleflex (TFX) Gets FDA Clearance for Arrow & TightTrack
07:26AM  Mazor Robotics (MZOR) Receives 25 System Orders in Q3
Oct-11-16 09:10AM  St. Jude (STJ) Launches EnSite Mapping System in Europe
Oct-10-16 09:20AM  Cepheid: Commercial Launch of Xpert Bladder Cancer Monitor
09:10AM  Becton Sells 50.1% Stake in Respiratory Business to Apax
Oct-07-16 08:15AM  St. Jude Medical (STJ) Announces US Launch of DBS System
Oct-06-16 09:54AM  Myriad Genetics Gets Selected for Hereditary Cancer Testing
Oct-05-16 10:49AM  St. Jude (STJ) Gets FDA Approval for BurstDR Stimulation
08:42AM  Trovagene's Liquid Biopsy to Participate in Precision Promise
08:40AM  TransEnterix (TRXC) Robots to Perform Radical Hysterectomy
08:23AM  Edwards Lifesciences' (EW) Acumen HPI Device Gains CE Mark
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications primarily in infectious diseases, POC women's and general health, and gastrointestinal diseases. The company offers Sofia influenza A+B and QuickVue influenza tests to detect viral antigens of influenza type A and B; Sofia strep A fluorescent immunoassay and QuickVue Strep A tests to detect group A Streptococcal antigen from throat swabs; and Sofia Respiratory Syncytial Virus (RSV), QuickVue RSV, and Quidel Molecular RSV + human metapneumovirus tests for respiratory syncytial virus. It also provides various products to detect various herpes simplex virus (HSV) and herpes family viruses; H&V-Mix to isolate HSV, VZV, and Cytomegalovirus; R-Mix to detect Influenza A and B, RSV, Adenovirus, and Parainfluenza types 1, 2, and 3; Sofia S. Pneomoniae fluorescent immunoassay (FIA) to detect pneumococcal pneumonia and meningitis; Sofia Legionella FIA to detect Legionella pneumophila seorgroup 1 antigen; AmpliVue Bordetella assay to detect Bordetella pertussis; and Lyra Adenovirus assay to detect human adenovirus viral DNA. In addition, the company offers Sofia hCG fluorescent immunoassay and QuickVue pregnancy tests to detect hCG in serum or urine; Thyretain for the diagnosis of graves disease; QuickVue Chlamydia test to detect Chlamydia trachomatis; Solana Trichomonas assay for the diagnosis of trichomoniasis; and clinical and research products for the assessment of osteoporosis and evaluation of bone resorption/formation. Further, it provides Lyra Direct C. difficile assay to detect Clostridium difficile Toxin A or Toxin B genes; Super E-Mix and D3 IFA Enterovirus indirect fluorescent antibody products; QuickVue fecal immunochemical test to detect the presence of blood in stool specimens; and serological tests to measure antibodies circulating in the blood. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BRYANT DOUGLAS CPresident & CEOJun 30Option Exercise12.3612,000148,320296,493Jun 30 07:59 PM
BRYANT DOUGLAS CPresident & CEOJun 30Sale27.2312,000326,760284,493Jun 30 07:59 PM
BRYANT DOUGLAS CPresident & CEOJun 29Option Exercise12.3612,000148,320296,493Jun 30 07:59 PM
BRYANT DOUGLAS CPresident & CEOJun 29Sale27.3312,000327,960284,493Jun 30 07:59 PM
BRYANT DOUGLAS CPresident & CEOJun 28Option Exercise12.3612,000148,320296,493Jun 30 07:59 PM
BRYANT DOUGLAS CPresident & CEOJun 28Sale27.3512,000328,200284,493Jun 30 07:59 PM
BRYANT DOUGLAS CPresident & CEOMay 31Option Exercise12.3612,000148,320296,493May 31 08:02 PM
BRYANT DOUGLAS CPresident & CEOMay 31Sale24.9312,000299,160284,493May 31 08:02 PM
BRYANT DOUGLAS CPresident & CEOMay 30Option Exercise12.3612,000148,320296,493May 31 08:02 PM
BRYANT DOUGLAS CPresident & CEOMay 30Sale25.1012,000301,200284,493May 31 08:02 PM
BRYANT DOUGLAS CPresident & CEOMay 26Option Exercise12.3612,000148,320296,493May 31 08:02 PM
BRYANT DOUGLAS CPresident & CEOMay 26Sale24.9012,000298,800284,493May 31 08:02 PM
WIDDER KENNETH JDirectorMay 17Option Exercise0.0096206,210May 18 08:11 PM
SLACIK CHARLES PDirectorMay 17Option Exercise0.0096202,601May 18 08:10 PM
POLAN MARY LAKE PH DDirectorMay 17Option Exercise0.00962013,012May 18 08:08 PM
BUECHLER KENNETH FDirectorMay 17Option Exercise0.001,263022,418May 18 08:06 PM
POLAN MARY LAKE PH DDirectorMay 14Option Exercise0.001,101010,432May 16 09:43 PM
WIDDER KENNETH JDirectorMay 05Option Exercise0.002,10703,226May 09 08:30 PM
BUECHLER KENNETH FDirectorMay 05Option Exercise0.004,315017,430May 09 08:29 PM
Brown Thomas DDirectorMay 05Option Exercise0.002,631042,041May 09 08:28 PM
Bujarski Robert JosephSVP, Bus Dev & Gen CounselMay 02Option Exercise12.6310,000126,30047,759May 03 08:18 PM
Bujarski Robert JosephSVP, Bus Dev & Gen CounselMay 02Sale24.5010,000245,00037,759May 03 08:18 PM
Bujarski Robert JosephSVP, Bus Dev & Gen CounselMay 01Option Exercise13.2626,225347,71857,759May 03 08:18 PM
Bujarski Robert JosephSVP, Bus Dev & Gen CounselMay 01Sale24.2033,225803,94837,759May 03 08:18 PM
BRYANT DOUGLAS CPresident & CEOApr 28Option Exercise12.3612,000148,320296,493Apr 28 08:02 PM
BRYANT DOUGLAS CPresident & CEOApr 28Sale24.2012,000290,400284,493Apr 28 08:02 PM
BRYANT DOUGLAS CPresident & CEOApr 27Option Exercise12.3612,000148,320296,493Apr 28 08:02 PM
BRYANT DOUGLAS CPresident & CEOApr 27Sale24.1612,000289,920284,493Apr 28 08:02 PM
BRYANT DOUGLAS CPresident & CEOApr 26Option Exercise12.3612,000148,320296,493Apr 28 08:02 PM
BRYANT DOUGLAS CPresident & CEOApr 26Sale24.1112,000289,320284,493Apr 28 08:02 PM
BRYANT DOUGLAS CPresident & CEOMar 31Option Exercise12.3612,000148,320296,493Mar 31 07:41 PM
BRYANT DOUGLAS CPresident & CEOMar 31Sale22.6912,000272,280284,493Mar 31 07:41 PM
BRYANT DOUGLAS CPresident & CEOMar 30Option Exercise12.3612,000148,320296,493Mar 31 07:41 PM
BRYANT DOUGLAS CPresident & CEOMar 30Sale22.5212,000270,240284,493Mar 31 07:41 PM
BRYANT DOUGLAS CPresident & CEOMar 29Option Exercise12.3613,080161,669297,573Mar 31 07:41 PM
BRYANT DOUGLAS CPresident & CEOMar 29Sale22.3013,080291,684284,493Mar 31 07:41 PM
POLAN MARY LAKE PH DDirectorMar 27Option Exercise13.979,331130,3549,331Mar 29 07:35 PM
BRYANT DOUGLAS CPresident & CEOFeb 28Option Exercise12.3626,920332,731307,226Feb 28 08:46 PM
BRYANT DOUGLAS CPresident & CEOFeb 28Sale21.3026,920573,288280,306Feb 28 08:46 PM
BRYANT DOUGLAS CPresident & CEOFeb 27Option Exercise10.5136,000378,522316,306Feb 28 08:46 PM
BRYANT DOUGLAS CPresident & CEOFeb 27Sale21.8236,000785,340280,306Feb 28 08:46 PM
BRYANT DOUGLAS CPresident & CEOFeb 24Option Exercise8.5044,000374,000322,958Feb 28 08:46 PM
BRYANT DOUGLAS CPresident & CEOFeb 24Sale21.1144,000928,686278,958Feb 28 08:46 PM
Brown Thomas DDirectorFeb 15Option Exercise13.979,331130,35439,410Mar 07 05:36 PM
Bujarski Robert JosephSVP, Bus Dev & Gen CounselDec 01Option Exercise15.282,71241,43944,608Dec 02 07:40 PM
Bujarski Robert JosephSVP, Bus Dev & Gen CounselDec 01Sale23.002,71262,37641,896Dec 02 07:40 PM
BRYANT DOUGLAS CPresident & CEONov 30Option Exercise8.5024,000204,000298,011Nov 30 07:39 PM
Bujarski Robert JosephSVP, Bus Dev & Gen CounselNov 30Option Exercise16.7739,288659,00174,896Dec 02 07:40 PM
Bujarski Robert JosephSVP, Bus Dev & Gen CounselNov 30Sale22.8357,2881,307,84541,896Dec 02 07:40 PM
BRYANT DOUGLAS CPresident & CEONov 30Sale22.8024,000547,200274,011Nov 30 07:39 PM
BRYANT DOUGLAS CPresident & CEONov 29Option Exercise8.5024,000204,000298,011Nov 30 07:39 PM
BRYANT DOUGLAS CPresident & CEONov 29Sale22.8424,000548,088274,011Nov 30 07:39 PM
BRYANT DOUGLAS CPresident & CEONov 28Option Exercise8.5024,000204,000298,011Nov 30 07:39 PM
BRYANT DOUGLAS CPresident & CEONov 28Sale23.0224,000552,480274,011Nov 30 07:39 PM
TAMERIUS JOHNSVP, Strat & Ext AffairsNov 25Option Exercise16.778,878148,88432,418Nov 29 08:08 PM
TAMERIUS JOHNSVP, Strat & Ext AffairsNov 25Sale23.508,878208,63323,540Nov 29 08:08 PM
BRYANT DOUGLAS CPresident & CEOSep 30Option Exercise8.5035,291299,974309,302Sep 30 08:56 PM
BRYANT DOUGLAS CPresident & CEOSep 30Sale22.0835,291779,225274,011Sep 30 08:56 PM
BRYANT DOUGLAS CPresident & CEOSep 29Option Exercise8.5016,767142,520290,778Sep 30 08:56 PM
BRYANT DOUGLAS CPresident & CEOSep 29Sale21.2216,767355,796274,011Sep 30 08:56 PM
BRYANT DOUGLAS CPresident & CEOSep 28Option Exercise8.5017,110145,435291,121Sep 30 08:56 PM
BRYANT DOUGLAS CPresident & CEOSep 28Sale21.6117,110369,747274,011Sep 30 08:56 PM
BRYANT DOUGLAS CPresident & CEOAug 30Option Exercise8.502,83224,072276,843Sep 01 08:00 PM
BRYANT DOUGLAS CPresident & CEOAug 30Sale22.002,83262,304274,011Sep 01 08:00 PM
TAMERIUS JOHNSVP, Strat & Ext AffairsAug 26Option Exercise15.715,00078,55023,540Aug 30 07:18 PM
Bujarski Robert JosephSVP, Bus Dev & Gen CounselAug 09Option Exercise17.3820,168350,52080,064Aug 09 08:43 PM
Bujarski Robert JosephSVP, Bus Dev & Gen CounselAug 09Sale22.5620,168454,91759,896Aug 09 08:43 PM
Bujarski Robert JosephSVP, Bus Dev & Gen CounselAug 08Option Exercise17.381,68529,28561,581Aug 09 08:43 PM
Bujarski Robert JosephSVP, Bus Dev & Gen CounselAug 08Sale22.731,68538,30159,896Aug 09 08:43 PM
Bujarski Robert JosephSVP, Bus Dev & Gen CounselAug 05Option Exercise17.382043,54660,100Aug 09 08:43 PM
Bujarski Robert JosephSVP, Bus Dev & Gen CounselAug 05Sale23.502044,79459,896Aug 09 08:43 PM
TAMERIUS JOHNSVP, Strat & Ext AffairsAug 01Sale23.027,000161,12418,540Aug 03 08:04 PM